Description:

Human [Arg³]Insulin-like Growth Factor-I ([Arg³]IGF-I) is a 70 amino acid analog of human IGF-I comprising the complete human IGF-I sequence with the substitution of an Arg for the Glu at position 3 (hence [Arg³]). GroPep scientists have engineered this analog with the express purpose of increasing biological activity. Human [Arg³]IGF-I is significantly more potent than human IGF-I in vitro and in vivo. It is offered to customers who prefer a full length IGF rather than the truncated human Des(1-3)IGF-I which has similar properties. The enhanced potency is due to the markedly decreased binding of human [Arg³]IGF-I to all IGF binding proteins which normally inhibit the biological actions of IGFs.

Human [Arg³]IGF-I is covered by the following patents assigned to GroPep:

US patent 5,164,370; European patent 346,429; Japanese patent 2,507,106; Australian patent 612,776; Canadian patent 1,341,204.

References:

King R. et al. (1992) J. Mol. Endocrinol. 8, 29-41
Francis G.L. et al. (1993) Biochem. J. 293, 713-719

Source:

Produced recombinantly

Purity:

> 95 % (by HPLC and N-terminal sequence analysis)

Molecular Weight:

7676 daltons – confirmed by Mass Spectrometry

N-terminal sequence analysis:

5 residues > 95 % single sequence

Biological Activity:

Type 1 IGF receptor binding assay: ED₅₀ < 10 ng/ml
IGF binding protein assay: ED₅₀ > 50 ng/ml
Stimulation of protein synthesis in rat L6 myoblasts: ED₅₀ < 10 ng/ml

Endotoxin:

< 0.1 EU/µg

State and Appearance:

Lyophilized white powder.
Dried from 100 mM acetic acid and stored under dry nitrogen at a slight vacuum (-25 kPa)

Storage/Stability:

At least 2 years at 2 - 4°C (lyophilized)

This is a Novozymes GroPep specification. ibt is authorized distributor of GroPep.

 Datasheet for (Arg3) IGF-I, recombinant protein (Receptor Grade)